Monitor for any future amendment converting this 13G to a 13D, which would signal activist intent. The stake is sizable but passive — no immediate catalyst.
Price Chart
Executive Summary
Invus Global Management, LLC and affiliated entities filed a Schedule 13G disclosing a passive 8.1% stake in City Therapeutics, Inc. (CTY), holding 4,302,772 shares as of October 16, 2026. The filing certifies no intent to influence control, indicating a routine passive investment by a healthcare-focused fund group.
Key Financial Metrics
Key Facts
- Invus Public Equities, L.P. holds 4,302,772 shares of City Therapeutics common stock, representing 8.1% of shares outstanding.
- Avicenna Life Sci Master Fund LP holds an additional 40,094 shares (0.1%), bringing the combined group total to 4,342,866 shares (8.1%).
- The filing is made under Rule 13d-1(c), certifying passive intent with no purpose of changing or influencing control.
- Shares outstanding used for percentage calculation: 51,721,168 as of October 16, 2026, plus 1,666,666 shares from underwriters' option exercise.
Financial Impact
8.1% passive stake valued at approximately $4.3 million based on 4,302,772 shares at an estimated price (no per-share price provided in filing).
Risk Factors
- Passive filing — no indication of engagement or value creation plans.
- Biotech sector risk; City Therapeutics is a pre-revenue clinical-stage company.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0002005369-26-000056 |
| Document: 0002005369-26-000056-index-headers.html | 0002005369-26-000056 |
| Document: 0002005369-26-000056-index.html | 0002005369-26-000056 |
| Document: 0002005369-26-000056.txt | 0002005369-26-000056 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D | $20.79 | awaiting T+1 | — | $21.19 (+1.95%) |
Oct 26, 2026 today | SC 13G | $20.79 | awaiting T+1 | — | $21.19 (+1.95%) |
Oct 22, 2026 4d ago | SC 13G | $20.77 $20.77 | · 0.00% | ▲ +0.52% | $21.19 (+2.05%) |
Oct 19, 2026 7d ago | Insider Cluster | $20.83 $20.43 | ▼ −1.92% | ▼ −2.45% | $21.19 (+1.75%) |
Oct 19, 2026 7d ago | Press Release | $20.83 $20.43 | ▼ −1.92% | ▼ −2.45% | $21.19 (+1.75%) |
Oct 16, 2026 10d ago | 424B4 | $21.46 $20.83 | ▼ −2.94% | ▼ −3.27% | $21.19 (−1.23%) |
Oct 16, 2026 11d ago | EFFECT | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.19 (−5.38%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.19 (−5.38%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.19 (−5.38%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.19 (−5.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers